Chicken Pox Info
Sunday, January 29, 2023
  • Home
  • Chickenpox
  • Monkeypox
  • Cowpox
  • Goatpox
  • Horsepox
  • Sheeppox
  • Squirrelpox
No Result
View All Result
  • Home
  • Chickenpox
  • Monkeypox
  • Cowpox
  • Goatpox
  • Horsepox
  • Sheeppox
  • Squirrelpox
No Result
View All Result
Chicken Pox Info
No Result
View All Result
Home Monkeypox

Thousands of vaccines for monkeypox ready in NZ, with a catch

Chickenpox Info by Chickenpox Info
January 9, 2023
in Monkeypox
0
Thousands of vaccines for monkeypox ready in NZ, with a catch
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

Global Monkeypox Treatment Market to reach US$ 249 million by 2033, Tecovirimat to account for 61% of all Therapeutic Approaches: Future Market Insights, Inc.


This 2003 electron microscope image shows mature, oval-shaped monkeypox virions, left, and spherical immature virions, right, obtained from a sample of human skin associated with the 2003 prairie dog outbreak.

This 2003 electron microscope image shows mature, oval-shaped monkeypox virions, left, and spherical immature virions, right, obtained from a sample of human skin associated with the 2003 prairie dog outbreak. (Source: Associated Press)

1News can reveal long-awaited vaccines for monkeypox are at the ready for widespread rollout.

But they’re not yet approved for use here, limiting any big promotion or marketing.

From Tuesday, people can complete an assessment to see if they are eligible.

The government wants to get the vaccines out quickly, however Medsafe still needs documentation from the manufacturer, meaning it will roll out as an “unapproved medicine”.

One expert thinks this hasn’t been done for vaccines in New Zealand before.

It is illegal to promote or advertise unapproved medicines.

That means the government won’t say the name of the vaccine even though it’s about to become available.

“That’s right, we can’t,” Associate Health Minister Ayesha Verrall told 1News.

“But we are making sure that everyone has the opportunity for a funded visit with their medical practitioner to discuss whether the vaccine is right for them,” she said.

The rollout comes after the government flagged in August it was working to secure the smallpox vaccine Jynneos.

Making unapproved medicines available is a route recognised in the Medicines Act, but those same laws stop brand names being promoted, or their availability being advertised.

Nikki Turner from the Immunisation Advisory Centre called it a “slightly unusual situation”.

“It is difficult to talk about a vaccine that hasn’t been approved in New Zealand,” she told 1News.

“However I’m confident to talk about this vaccine because it does have international approval. It would be really good to get New Zealand approval to make it easier to spread information about it,” she said.

The government is equally confident it can still reach the people it needs to.

“We’re able to offer this vaccine even though it has not yet been approved by Medsafe provided people have a consultation with a medical practitioner,” Verrall said.

“We had a group of independent experts review the vaccine and they made a recommendation that we don’t delay making an offer under this avenue.”

One of the reasons unapproved medicines can be allowed is if they are available overseas and have “acceptable quality, efficacy and safety,” and when approval in New Zealand hasn’t happened,” Medsafe says.

This vaccine is available in Australia, the United Kingdom, and the United States.

“We’ve acted as fast as we can,” Verrall said.

“The company who made the vaccine needs to submit the full set of information to Medsafe, as soon as Medsafe receives that information they’ll be able to complete their assessment.”

There have been 5000 vials of the smallpox vaccine obtained, enough for 20,000 people.

It comes amid a global shortage and more is expected to arrive later in the year.

The vaccine will be available for prescribing to eligible people from Monday January 16.

Joe Rich, from the Burnett Foundation, said his organisation had no safety concerns about the vaccine.

“It does create a bit of a frustration for us. While it’s unapproved we’re not allowed to promote it, which his challenging when we want to be getting as many people as possible,” he said.

“We know many in our community have been waiting to get access to the Mpox vaccine, so it’s very exciting.”

There have been 41 cases of monkeypox in New Zealand since the outbreak started.

Globally, there have been more than 83,000 cases in 110 countries with 66 deaths.

Infections, though, are waning.

The World Health Organization has signalled it hopes to declare an end to the emergency this year.

Who is eligible?

Those initially eligible for the vaccine include:

  • Close physical contacts of people infected with Mpox, such as sexual partners and people who live in the same household.
  • Gay, bisexual and other men who have sex with men (GBMSM) who have multiple sexual partners, and trans and cisgender women who are in intimate relationships with these eligible men.
  • Those recommended to have the vaccine by medical specialists

What does the law say?

The vaccine can only be made available under section 29 of the Medicines Act 1981. This allows for ‘unapproved’ vaccines to be provided to individual medical practitioners for a particular patient after assessing the patient’s needs. The Act also prevents the brand name of the vaccine being promoted due to its ‘unapproved’ status.

Advertising the availability of unapproved medicines is prohibited by section 20 of the Medicines Act 1981. This means that the vaccine cannot be advertised, nor its availability promoted. It can only be offered by a medical practitioner to a consumer as a proposed medical treatment and then administered after a full informed consent process.

ShareTweetPin
Chickenpox Info

Chickenpox Info

Related Posts

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

by Chickenpox Info
January 27, 2023
0

Pharmacists should consider 2 critical safety issues when treating or vaccinating patients for monkeypox.First, it is vital to understand that...

Global Monkeypox Treatment Market to reach US$ 249 million by 2033, Tecovirimat to account for 61% of all Therapeutic Approaches: Future Market Insights, Inc.

Global Monkeypox Treatment Market to reach US$ 249 million by 2033, Tecovirimat to account for 61% of all Therapeutic Approaches: Future Market Insights, Inc.

by Chickenpox Info
January 27, 2023
0

Future Market Insights Global and Consulting Pvt. Ltd.Asia Pacific Monkeypox Treatment Market is projected to witness the fastest growth of...

Global Monkeypox Treatment Market to reach US$ 249 million

Global Monkeypox Treatment Market to reach US$ 249 million

by Chickenpox Info
January 27, 2023
0

DUBAI, United Arab Emirates, Jan. 26, 2023 (GLOBE NEWSWIRE) -- A recent Future Market Insights report on the monkeypox treatment...

Florida Health Orange County

DOH-Orange MPOX / Monkeypox Vaccination Update #12

by Chickenpox Info
January 26, 2023
0

Contact: Kent Donahue Kent.Donahue@flhealth.gov407-858-1418  ORLANDO, FL – The following update is provided to keep the community informed on the Florida Department...

Study: Clinical Testing of Pediatric Mpox Specimens: Unique Features and Challenges in a Low Prevalence Population. Image Credit: Dotted Yeti / Shutterstock

An evaluation of pediatric Mpox specimens

by Chickenpox Info
January 25, 2023
0

In a recent study posted to the medRxiv* preprint server, researchers in the United States performed the clinical evaluation of...

Next Post
BD, CerTest win FDA EUA for monkeypox diagnostic

BD, CerTest win FDA EUA for monkeypox diagnostic

Monkeypox Virus Has Potential to Be Sexually Transmitted

Monkeypox Virus Has Potential to Be Sexually Transmitted

RECOMMENDED

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

January 27, 2023
Global Monkeypox Treatment Market to reach US$ 249 million

Global Monkeypox Treatment Market to reach US$ 249 million

January 27, 2023

MOST VIEWED

  • Can you catch chickenpox twice? How contagious is virus and symptoms explained

    How long does chickenpox last? When do symptoms go away, how long is it contagious – and is there treatment

    0 shares
    Share 0 Tweet 0
  • What happened to monkeypox? Answers to your most pressing questions.

    0 shares
    Share 0 Tweet 0
  • TikTok craze of using calamine lotion as makeup causing chickenpox treatment shortages, pharmacy warns

    0 shares
    Share 0 Tweet 0
  • Research finds link between chickenpox and Alzheimer’s

    0 shares
    Share 0 Tweet 0
  • Can monkeypox spread through contaminated food?

    0 shares
    Share 0 Tweet 0

Chicken Pox Info

Welcome to Chicken Pox Info, where you will get all the latest news about all the different pox diseases, to stay up to date, and to protect yourself.

CATEGORY

  • Chickenpox
  • Cowpox
  • Goatpox
  • Horsepox
  • Monkeypox
  • Sheeppox
  • Squirrelpox

Site Links

  • Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

Latest News

  • Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox
  • Global Monkeypox Treatment Market to reach US$ 249 million
  • Global Monkeypox Treatment Market to reach US$ 249 million by 2033, Tecovirimat to account for 61% of all Therapeutic Approaches: Future Market Insights, Inc.

Copyright © 2022 Chickenpoxinfo.com | All Rights Reserved.

No Result
View All Result
  • Home
  • Chickenpox
  • Monkeypox
  • Cowpox
  • Goatpox
  • Horsepox
  • Sheeppox
  • Squirrelpox

Copyright © 2022 Chickenpoxinfo.com | All Rights Reserved.

What Are Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT